细胞角蛋白19和半乳糖凝集素3在甲状腺滤泡上皮乳头状微小病变中的表达及临床意义  

The Clinical Significance for Expression of Cytokeratin 19 and Galectin-3 in Micropapillary Lesion of Thyroid

作　　者：胡艳萍[1] 刘凤阁[1] 崔莉[1] 吴林林[1] 杨建杰[1] 

机构地区：[1]北京市潞河医院病理科,北京101149

出　　处：《临床误诊误治》2011年第1期8-10,I0001,共4页Clinical Misdiagnosis & Mistherapy

摘　　要：目的分析细胞角蛋白19（CK19）和半乳糖凝集素3（Galectin-3）在甲状腺滤泡上皮乳头状微小病变中的表达情况。方法采用免疫组织化学染色方法检测32例甲状腺乳头状微小癌（papillary microcarcinoma of thyroid,PM-CT）（微小癌组）与28例甲状腺良性病变伴微灶滤泡上皮乳头状增生（良性病变组）CK19和Galectin-3的表达情况,所有病例术后随访1~96个月。结果 CK19和Galectin-3在微小癌组中阳性表达率分别为93.75%及96.88%,而在良性病变组表达率分别为6.25%及17.86%,两组比较差异有统计学意义（P〈0.01）。随访期间,除2例PMCT失访外,余30例PMCT及28例甲状腺良性病变患者均健在,无复发或转移病例。结论 CK19和Galectin-3对鉴别诊断PMCT与甲状腺良性病变伴微灶滤泡上皮乳头状增生具有重要的临床应用价值,可作为早期PMCT的辅助病理诊断依据。PMCT预后较好,对于偶然发现或低危的PMCT可术后长期观察。Objective To analysize the expression of CK19 and Galectin-3 in micropapillary lesion of thyroid.Methods By immunohistochemical method,the expression of CK19 and Galectin-3 was detected in 32 cases of PMCT and 28 cases of benign thyroid disease with micropapillary hyperplasia benign lesion group,and the follow-up data for 1-96 months were kept for all cases after surgical managment.Results The expression rate of CK19 and Galectin-3 was 93.75% and 96.88% respectively in PMCT,and was 6.25% and 17.86% respectively in benign lesion group.There was statistical significant difference between two groups（P0.01）,the follow-up data was kept for all cases except 2 cases,no recurrence and death was found in 30 PMCTs and in 28 benign thyroid disease.Conclusion CK19 and Galectin-3 show significant clinical value in early diagnosis for PMCT,and in differential diagnosis for benign thyroid disease with micropapillary hyperplasia.The PMCT has a good prognosis,and keeping long time follow-up could achieve fairly good effect on incidentally detected and low-risk PMCT.

关 键 词：甲状腺 癌 乳头状 滤泡 细胞角蛋白19 半乳糖凝集素3 免疫组织化学 

分 类 号：R736.1[医药卫生—肿瘤]